Synopsys, Inc. (NASDAQ:SNPS – Get Free Report) insider Janet Lee sold 250 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $510.00, for a total value of $127,500.00. Following the completion of the sale, the insider directly owned 12,209 shares of the company’s stock, valued at $6,226,590. This trade represents a 2.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Synopsys Trading Down 1.0%
Shares of NASDAQ SNPS traded down $5.21 during trading on Thursday, hitting $514.49. 1,359,995 shares of the company were exchanged, compared to its average volume of 1,935,757. The company has a fifty day moving average price of $442.21 and a 200-day moving average price of $503.94. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.52 and a current ratio of 1.62. The firm has a market capitalization of $98.43 billion, a PE ratio of 64.39, a P/E/G ratio of 4.23 and a beta of 1.12. Synopsys, Inc. has a 12-month low of $365.74 and a 12-month high of $651.73.
Synopsys (NASDAQ:SNPS – Get Free Report) last announced its quarterly earnings data on Wednesday, December 10th. The semiconductor company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.11. Synopsys had a net margin of 18.89% and a return on equity of 7.89%. The firm had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.25 billion. During the same quarter in the prior year, the firm posted $3.40 earnings per share. Synopsys’s quarterly revenue was up 37.8% on a year-over-year basis. Synopsys has set its FY 2026 guidance at 14.320-14.400 EPS and its Q1 2026 guidance at 3.520-3.580 EPS. As a group, equities research analysts expect that Synopsys, Inc. will post 10.64 EPS for the current year.
Hedge Funds Weigh In On Synopsys
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on SNPS shares. KeyCorp raised their target price on Synopsys from $575.00 to $600.00 and gave the stock an “overweight” rating in a research note on Thursday, December 11th. Zacks Research raised Synopsys from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Rosenblatt Securities upgraded shares of Synopsys from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $605.00 to $560.00 in a report on Tuesday, December 9th. Stifel Nicolaus lowered their target price on shares of Synopsys from $650.00 to $550.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. Finally, Needham & Company LLC boosted their price target on shares of Synopsys from $550.00 to $580.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Eleven research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $562.13.
View Our Latest Stock Analysis on Synopsys
Synopsys Company Profile
Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.
In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.
Featured Articles
- Five stocks we like better than Synopsys
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Market Panic: Trump Just Dropped a Bomb on Your Stocks
- YDES Could Be 2026’s Biotech Breakthrough
- Hit Your Retirement “Freedom Number” (Without $1 Million)
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.
